On January 17, 2008 Cancer Research Technology Limited (CRT), the specialist oncology-focused development and commercialisation company, reported it has granted an exclusive worldwide licence to Glycart Biotechnology, a member of the Roche group, to develop a preclinical antibody for the treatment of cancer (Press release, Cancer Research Technology, JAN 17, 2008, View Source [SID1234523382]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The licensed antibody selectively binds to a cell surface-presented protein that is over-expressed in certain types of cancer including colorectal cancer. The antibody was originally developed by Cancer Research UK.

Glycart will use its proprietary GlycoMAB technology to enhance the in vivo efficacy of the antibody. A research collaboration between CRT, Glycart and the University of Oxford has been established to investigate the potential efficacy of the glyco-engineered antibody in pre-clinical studies.

Dr Phil L’Huillier, CRT’s director of business management, said: "This is a significant step forward in the development of this technology as a therapeutic agent. We’re very pleased that Glycart is taking this exciting antibody forward and we look forward to the development of a therapeutic that will help treat bowel cancer more efficiently."